Related Experiment Video
Updated: May 24, 2025

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
Published on: August 9, 2022
CardiOT: Towards Interpretable Drug Cardiotoxicity Prediction Using Optimal Transport and Kolmogorov--Arnold Networks
Abstract:
Investigating the inhibitory effects of compounds on cardiac ion channels is essential for assessing cardiac drug safety. Consequently, researchers have developed computational models to evaluate combined cardiotoxicity (CCT) on cardiac ion channels. However, limitations in experimental data often cause issues like uneven data distribution and scarcity. Additionally, existing models primarily emphasize atomic information flow within graph neural networks (GNNs) while overlooking chemical bonds, leading to inadequate recognition of key structures. Therefore, this study integrates optimal transport (OT), structure remapping (SR), and Kolmogorov-Arnold networks (KANs) into a GNN-based CCT prediction model, CardiOT. First, the proposed CardiOT model employs OT pooling to optimize sample-feature joint distribution using expectation maximization, identifying "important" sample-feature pairs. Additionally, SR technology is used to emphasize the role of chemical bond information in message propagation. KAN technology is integrated to greatly enhance model interpretability. In summary, the model mitigates challenges related to uneven data distribution and scarcity. Multiple experiments on public datasets confirm the model's robust performance. We anticipate that this model will provide deeper insights into compound inhibition mechanisms on cardiac ion channels and reduce toxicity risks.
Insights
This study introduces CardiOT, a novel computational model for predicting combined cardiotoxicity (CCT) in drugs. By integrating optimal transport and advanced neural networks, it improves accuracy despite data limitations, enhancing cardiac drug safety assessments.
Area of Science:
- Computational chemistry
- Drug discovery
- Cardiovascular pharmacology
Background:
- Assessing cardiac drug safety requires investigating compound effects on cardiac ion channels.
- Computational models for combined cardiotoxicity (CCT) prediction face challenges due to experimental data scarcity and uneven distribution.
- Existing graph neural network (GNN) models overlook chemical bond information, limiting structural recognition.
Purpose of the Study:
- To develop an advanced GNN-based model, CardiOT, for accurate CCT prediction.
- To address data limitations and enhance the recognition of crucial chemical structures in cardiotoxicity assessment.
- To improve the interpretability of cardiotoxicity prediction models.
Main Methods:
- Integration of optimal transport (OT), structure remapping (SR), and Kolmogorov-Arnold networks (KANs) into a GNN framework.
- Utilizing OT pooling with expectation maximization to optimize sample-feature distributions and identify key pairs.
- Employing SR technology to emphasize chemical bond information during message propagation within the GNN.
Main Results:
- The CardiOT model effectively mitigates issues of uneven data distribution and scarcity.
- Demonstrated robust performance across multiple public datasets.
- Enhanced model interpretability through the integration of KAN technology.
Conclusions:
- CardiOT offers a significant advancement in predicting compound inhibition on cardiac ion channels.
- The model is expected to reduce toxicity risks in drug development.
- Provides deeper insights into the mechanisms of compound-cardiac ion channel interactions.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
10:30Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: August 4, 2022
Related Concept Videos
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...
Analysis of Population Pharmacokinetic Data